Asthma control in pediatric patients treated with once-daily or twice-daily nebulized budesonide inhalation suspension (Pulmicort Respules)

Allergy and Asthma Proceedings

Volumn 29, Issue 3, 2008, Pages 280-285

  Baker, James W ^a,d   Kemp, James ^b   Uryniak, Tom ^c   Silkoff, Philip E ^c  

^a Allergy Asthma and Dermatology Research Center LLC   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Baker Allergy   (United States)

Author keywords

Asthma; Asthma control days; Budesonide inhalation suspension; Nebulizer; Once daily treatment; Pediatrics; Rescue medication free days; Retrospective study; Symptom free days; Twice daily treatment

Indexed keywords

BUDESONIDE;

ARTICLE; ASTHMA; CHILD; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; IMMUNOLOGY; INFANT; INHALATIONAL DRUG ADMINISTRATION; MALE; NEBULIZER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; ASTHMA; BUDESONIDE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; NEBULIZERS AND VAPORIZERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 46649115895     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3113     Document Type: Article

References (11)

1. National Asthma Education and Prevention Program. Full Report of the Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma (EPR-3). August 2007, Publication No. 08-4051, National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI), Bethesda, MD, 2007.
2. Carranza Rosenzweig JR, Edwards L, Lincourt W, et al. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 98:1157-1165, 2004.
3. Pulmicort Respules (budesonide inhalation suspension) package insert. Wilmington, DE: AstraZeneca LP, January 2007.
4. Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 102:789-796, 1998.
5. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 103:414-421, 1999.
6. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 83:231-239, 1999.
7. Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc 22:359-366, 2001.
8. Fiocchi A, Terracciano L, Martelli A, et al. The natural history of childhood-onset asthma. Allergy Asthma Proc 27:178-185, 2006.
9. Mikhak Z. Dose-response studies of fluticasone propionate and budesonide: Classification based on asthma severity. Allergy Asthma Proc 27:402-411, 2006.
10. Sorkness CA, Lemanske RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119:64-72, 2007.
11. Garcia Garcia LM, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics 116:360-369, 2005.